HemaCare Corp. (fka HEMA)

[Renee]

HEMA: Acquired by Charles River Laboratories International, Inc. (CRL). Each outstanding share of common stock will be canceled and converted solely into the right to receive $25.40 in cash.

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[dg33]

So, after all your questions that I told you were not relevant, did you buy shares of the stock?

[Steve07]

Can you point to where it is false?

[dg33]

As a health care provider and having worked at the FDA for 10 years I can tell you that you are wildly off with your claims. I'm not sure what your purpose is on this board other than to be a generator of false information. You are now on ignore.

[Steve07]

DG33 it appears that you don't have a fundamental understanding of the Hemacare business. It appears The majority of the Hemacare business are derivative blood bank businesses that non-for-profit blood banks in the US can not charge for, because of regulations. Every blood bank has tons of donors and databases. Every blood banks can generate this products in large quantities but can't charge for them. I suspect that for the most part those are available in China without problem. There might be some niche products on a very small scale. So other than the PR value there is nothing there. I would also recommend to you to do some research regarding the money behind Allcells.

I would also recommend you do some research who is on the BOD of Hemacare. I would ask myself why are there two non-for-profit CEOs on the board and what that means for a the possibility on non-possibility of a buyout.

If you look at the history of the blood bank business and Hemacare, you might conclude that Hemacare is on borrowed time until the regulatory environment catches like it did in the past. There is a reason why Hemacare is the only public blood bank related company.

There are more questions. But let's leave some for the future.

[dg33]

> It appears that this Charles River announcement is a PR stunt
> with zero consequences in the real word just like the rat kit a
> year ago.

And you know that how? Have you called the CEO of HEMA and asked what the financial implications are of the China deal with Charles River? From the recent press release:

"Vital River will offer HemaCare’s full line of high-quality human primary cells and tissues to researchers in China. Vital River currently provides products to a vast number of scientists focused on benchtop research and drug discovery.

“We are excited to continue expanding our relationship with Charles River and partner with their Vital River subsidiary to continue to strengthen and expand our global presence,” said Pete van der Wal, President and CEO of HemaCare. “China represents a tremendous market for us, and Vital River, as the leading provider of tools and services for biopharmaceutical research in China, is the ideal partner to further drive our growth in this exciting, rapidly growing market.”

[Steve07]

While Allcells products are sold under the Lonza name, It appears that Hema has only a resale agreement. Regardless, China is not a huge research center. The regulatory environment in China is less restrictive. In an industry with no barrier to entry and IP, China can set its on operation quickly. It appears that this Charles River announcement is a PR stunt with zero consequences in the real word just like the rat kit a year ago.

[dg33]

It's great that HEMA was able to team up with Charles River to compete with AllCells in China. It would be interesting to know how the medical research community views one company's products and services versus the other.

[Steve07]

It appears that Lonza elected to team up with Hemacare's competitor Allcells. Allcells has deep China connections (look the at the profile of the owners). It appears that Since the Lonza teaming with Allcells occurred first, Charles River ended up with Hemacare.

https://www.allcells.com/lonza-and-allcells-join-forces-for-global-commercialization-of-hematopoietic-primary-cells/

[Steve07]

[Steve07]

[Steve07]

[Steve07]

It appears that Lonza elected to team up with Hemacare's competitor Allcells. Allcells has deep China connections (look the at the profile of the owners). It appears that Since the Lonza teaming with Allcells occurred first, Charles River ended up with Hemacare.

https://www.allcells.com/lonza-and-allcells-join-forces-for-global-commercialization-of-hematopoietic-primary-cells/

[dg33]

Here's what makes HEMA special:

Read the section, especially, on the comment from the SVP at Charles River and the reason for HEMA's increasing number of partnerships with Charles River (if you don't know about Charles River you may want to look them up - ticker- CRL) :

https://finance.yahoo.com/news/hemacare-charles-river-laboratories-partner-121000606.html

[dg33]

1. They do not have a massive number of shares. Read the quarterly report that was just issued to have your share questions answered.
2. They are a rapidly growing company in a new, greatly expanded facility. My guess is that they would rather see the money go towards their business than the SEC.
3. Would you ask why can't any hospital create the highest quality cancer treatment center in the world? It is difficult to do what they did. They have a huge database of paid donors, top scientists, extraordinary quality control and excellent management. They have also been highly innovative. Most companies stay within their niche. HemaCare went way outside their box to become one of the best in what they do.

[Steve07]

If I am not mistaken, this is a pink sheet company! I think it means it is not subject to the same disclosure requirements as the companies that are fully registered with the SEC.
The company shows 13,657,206 issued shares on this report
The company shows 12,139,045 issued shares on the 2018 report
The company shows 11,612.759 issued shares on the 2017 report

I have the following questions:
- Given the profitability of the company what is the reason Hemacare is not registered with the SEC?
- Who are the beneficiaries of this massive share issuance?
- Since the company went off registration sometime in the 2007-8, How many of the 13,657,206 shares are registered for free trading?
- If all the shares of the company were registered and free to trade what would be the realistic price of Hemacare?
- Given that to my knowledge, the company has no intellectual properties, what prevents any blood bank to establish a subsidiary to do exactly what Hemacare does?

[dg33]

"China represents an additional 1.4 billion potential customers"

Could you please explain what you mean by that statement? HemaCare products are used by people conducting medical research in pursuit of drug development or for basic science research purposes.

[Bogie80]

Did anyone catch the paragraph on the 2nd page of the annual report mentioning new news about expanding into China (while expanding relations with Charles River Laboratories)?

“On November 26, 2018, HemaCare signed a distribution agreement with Charles River Laboratories subsidiary, Vital River, to provide the scientific community in China with a direct access to healthy and disease state human primary cells. Beijing Vital River Laboratory Animal Technology Co., Ltd is a subsidiary of Charles River Laboratories and the premier commerce provider of research models and related services to the scientific community in China. Vital Rivers was chosen as a partner to expanse China distribution because of HemaCare’s successful and growing global relationships with Charles River Laboratories.”

China represents an additional 1.4 billion potential customers that can also eventually become HEMA human biological donors. This is great news and I am always adding to my Hema position. We are still in the second chapter of our story and the sky is the limit.


L-

[snakess]

Excellent six months report released today. growth, cash, partnerships,no debt, earnings,new building, building management. This is a winner and price appreciation is in the cards for years to come.
We have followed this stock since .40/sh now $13- new high $16 the other day http://www.saadvisory.com

[Ihun]

I had my doubts about this comp but after looking at the recent biannual report I am confident that the company's turnaround is not only legit but also sustainable to the point where it could turn into a blue chip down the road.

[dg33]

Finally, a voice in the wilderness.

Clearly, someone or a number of people found out what we've known for a while. The CEO's letter to shareholders https://www.hemacare.com/wp-content/uploads/2018/05/2017-Annual-Report_Final.pdf is a worthwhile read, especially this line-- "we continue transforming HemaCare to become the preferred supplier of human biological materials supporting immunotherapy, cell therapy, and regenerative medicine worldwide. We look forward to maximizing the future of the company and all the potential it holds". Their industry is predicted to have a $2.5B market value in 2024.

They are more than doubling their operational space, increasing efficiency of product development, expanding to a far greater degree into markets worldwide and buying new state of the art equipment.

I have no idea what the shares will be selling for in 2 years but given that the company is under the radar and has yet to be up listed (I believe they are focusing on growing the company and will let the share price take care of itself, rather than focusing attention where it's not needed at the moment), the future could be as exciting as what we've experienced over the past 2 years.

[snakess]

Huge move the past few days especially today where it traded as high as $11.00 on extra ordinary volume. Could something big be in the works?
Large money is being thrown at this cutting edge medical tech company . We had almost $600k worth of trading today. We see no news, but there is a huge buyer around and gobbling up cheap paper in his or her opinion

[dg33]

In 2017 HEMA had $20M in revenue. In 2015 they estimated the market for their products and services to be $500M with an expected tripling of that market by 2025. During 2018 they will be increasing the number of employees, moving to a much larger facility, moving into new markets and purchasing new equipment to prepare for the continuing and increasing demand for their products and services. In 2018 growth is expected to less than the previous 3 years due to the aforementioned capital expenditures. However, this is clearly an undiscovered gem in the biotech industry. With only 12M shares outstanding the stock could readily skyrocket over the next few years. A move to NASDAQ will hopefully occur in the not too distant future, however, they have mentioned nothing in that regard as of today.

[dg33]

Good write-up. Interesting how what he wrote about Zoom (ZMTP) may have moved the stock today but zero impact on HEMA. Of course meaningless long term as both stocks should do very well.

[snakess]

updated and strong buy recommendation on hema from noted financial publication since 1984 best earnings report of any microcap http://saadvisory.com/update/archive/April-01-2018.htm

[dg33]

Thank you for your permission. Now I can sleep well tonight.

[snakess]

dg please don't be so PC- if you want to mention zmtp you have my permission. So it is a thread on hema- some investor's as few as there
may be might be interested. Stop the PC bull

[dg33]

HEMA and ZMTP are my two largest holdings. That so many people are unaware of both companies especially given that they are potential blockbuster stocks is beyond belief. That will change. This board is about HEMA so this will be my last time mentioning ZMTP.

[snakess]

hema ! this report by hema could actually be the best micro-cap year-end result i have seen this year. Firing on all cylinders- great earnings - huge rev growth and that does not even hint of the recent partnership with
the billion dollar company! growth by 60%, cash horde, partnerships, i more tranche from oneblood and new facilities. Maybe NASDAQ listing is next and we ring the bell and the stock goes to $15.00- could even be a buyout candidate. Only trading at 20x or 15x actual depending if you add in the tax advantage. Growing by 60% - give a PE of 30 we then have a $9.00 or $12 stock
other fav zmtp read the latest 10k another real sleeper in bed with MOTOROLA big time

[Bogie80]

Congrats to all HEMA longs! Earnings were incredible:

---.37eps (~.29 without the tax benefit) vs. .065 last year.
--- 4.4 mil net income vs 780k .
--- Cash on hand wet from ~2.2 to ~9.2 mil

Now let's look at the short term/long term prospects:

---Assets to Liabilities: 17.4 mil : 2.7 mil (6.4:1)
---Current Ratio: 14.9 mil : 2.65 mil (5.6:1)

***Anything over 2:1 is very strong. We are demolishing that rule of thumb (we will be bringing in a lot more then paying out).

This is taken to the next level when we take a look at the AR:AP ratio (2:1 great here too): 2.9 mil:680k (4.26:1).

Now take into account we will be moving into a 3x bigger facility shortly to "keep up with demand"....and we just teamed up with a 5 billion dollar partner (Charles River Laboratories) to revolutionize the medical industry. Keep in mind CRL tested 70% of the drugs approved by the FDA last year. YES 70%.

Humanization kits (rat+disease in a box) are used for practically every type of disease testing. CRL teaming up with HEMA (to revolution humanization kits) will allow for much faster, and less expensive testing. All of Hema's specimens are pre approved saving testing time and funds. Oh and by the way, HEMA has blood, stem cells, etc. for practically every major form of cancer and countless other conditions (autism, herpes, ulcers, diabetes, HIV, hepatitis, etc. etc.).

To spell things out...HEMA should be directly involved with a majority of the disease testing conducted by one of the largest labs that tested 70% of the drugs the FDA approved last year.

This is so huge it is impossible to put a long term estimate on HEMA. If things keep progressing in this fashion the sky is the limit. For now I think we have graduated to a 10-20$ valuation over then next 12 months.

Cheers.


B-

[dg33]

Do you have a sense of the potential market cap for HEMA? It will grow over time but I wonder what its long-term potential (3 - 5 years out, let's say) might be.

[dg33]

2017 Financial Report Released Today

https://finance.yahoo.com/news/hemacare-reports-full-2017-results-130000086.html

Outstanding results for 2017. I can't believe how few shares trade in such a profitable company with millions in cash and an extraordinarily bright future. I can't wait until the day when a 100 share trade doesn't cause the stock to move .80 in one direction or the other.

[snakess]

It appears that there are large buyer around. Either there is a takeover suitor or a fund cobbling up shares at a rapid pace. Since Oneblood
bought their position this stock has been on a upside tear. I believe that the numbers from year end are great and someone knows and the value
of the company has been mispriced. Rem when Oneblood bought initial position the stock was around $1 and Oneblood paid $3.44 early Jan Oneblood bought the 2nd tranche at the same price. One can only assume that their partnership has been extremely favorable so buyer are everywhere and the stock pushes higher. I assume the company is getting closer to filing for nasdaq listing. This will bring institutional investors on board and might even cause an IPO with a regional brokerage house in Cal and or New York.
In many cases investor's are always looking to get out , but with hema
investors are looking to get in. The majority of holders are not selling because HEMA offers cutting edge biotech for pharma and biopharma.
Year end numbers released in around 45 days.

[dg33]

HemaCare Announces OneBlood Exercises Second Investment Tranche Option

Business WireJanuary 8, 2018

LOS ANGELES--(BUSINESS WIRE)--

HemaCare Corporation (HEMA), a leading provider of human-derived primary blood cells and tissues for biomedical research, has announced a second tranche investment, effective December 28, 2017, by a wholly-owned subsidiary of OneBlood, Inc., a not-for-profit blood center based in Florida. Under the terms of the agreement signed January 6, 2017, OneBlood is purchasing an additional 363,786 shares at $3.44 per share.

“OneBlood is an industry-leading blood center that is known for its innovative and progressive approaches. Based on HemaCare’s sustained outstanding performance, OneBlood’s wholly-owned subsidiary exercised their option to make the second tranche investment,” said Pete van der Wal, Chief Executive Officer for HemaCare. “In addition, both parties continue performing according to the terms of the Sales and Distribution Agreement executed in January, 2017,” said van der Wal.

“The partnership with HemaCare is mutually beneficial,” said Mr. Scholl, Chief Executive Officer for OneBlood. “We are excited to be a part of an initiative that is helping provide scientists and clinical researchers with what they need to find the next generation of medical cures,” said Scholl.

[dg33]

As far as I know, that option to buy more at 3.44 was not executed.

[snakess]

new 52 wk high today- $3.75- no news but this stock has been basing for a very long time and maybe we are breaking out. The funding source has the option to buy another 1.25 million shares @ 3.44 by year end. Maybe some quarterly numbers, presser, funding, listing on exchange. or nothing at all.
regardless strong buy

[snakess]

bullish announcement from company today- expanding product line- should get earnings report soon so the stock should break out to higher highs. This company could be $10 sooner than later. Once the herd figures it out look out above

[paideia]

Here's a bunch of research right up HEMA's alley ...


MicroRNAs Can Effectively Induce Formation of Insulin-Producing Cells from Mesenchymal Stem Cells

The function of microRNAs in the formation of insulin-producing cells from adult stem cells is poorly understood. Scientists examined the microRNA expression profile in nestin-positive umbilical cord-derived mesenchymal stem cells and nestin-positive pancreatic mesenchymal stem cells using a deep sequencing approach. [J Tissue Eng Regen Med] Abstract

Pre-Incubation with hucMSC-Exosomes Prevents Cisplatin-Induced Nephrotoxicity by Activating Autophagy

Investigators demonstrated that the pretreatment of human umbilical cord mesenchymal stem cell-derived exosomes (hucMSC-Ex) can prevent the development of cisplatin-induced renal toxicity by activation of autophagy in vitro and in vivo. HucMSC-Ex inhibited cisplatin-induced mitochondrial apoptosis and secretion of inflammatory cytokines in renal tubular epithelial cells in vitro. [Stem Cell Res Ther] Full Article

Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial

Scientists hypothesized that umbilical cord blood-derived cell therapies may have potential in alleviating autism spectrum disorder symptoms by modulating inflammatory processes in the brain. Significant improvements in children's behavior were observed on parent-report measures of social communication skills and autism symptoms, clinician ratings of overall autism symptom severity and degree of improvement, standardized measures of expressive vocabulary, and objective eye-tracking measures of children's attention to social stimuli. [Stem Cells Transl Med] Abstract | Full Article | Press Release

Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and Hospitalization

In a Phase I study, adult recipients of umbilical cord blood (UCB) stem cells cultured ex vivo for three weeks with nicotinamide (NiCord) had earlier median neutrophil recovery compared to historical controls. To evaluate the impact of faster neutrophil recovery on clinically relevant early outcomes, the authors reviewed infection episodes and hospitalization during the first 100 days in an enlarged cohort of 18 NiCord recipients compared to 86 standard UCB recipients at their institution. [Biol Blood Marrow Transplant] Abstract

Arachidonic Acid and Docosahexanoic Acid Enhance Platelet Formation from Human Apheresis-Derived CD34+ Cells

Blood banks frequently face a shortage of platelets. Therefore, methods to generate platelets on a large scale are strongly desirable. However, to generate megakaryocytes and platelets (PLTs) in numbers sufficient for clinical application, it is essential to understand the mechanism of platelet production and explore efficient strategies accordingly. Researchers found a significant enhancement in cell numbers, surface marker expression, cellular ploidy and expression of cytoskeletal components during PLT biogenesis in cultures exposed to media containing arachidonic acid/docosahexanoic acid than control cultures that were not exposed to these poly-unsaturated fatty acids. [Cell Cycle] Abstract

Human Umbilical Cord Mesenchymal Stromal Cells Improve Survival and Bacterial Clearance in Neonatal Sepsis in Rats

Investigators hypothesized that human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) improve survival in experimental neonatal sepsis. Treatment with either hUC-MSCs or preconditioned hUC-MSCs significantly increased survival. Both hUC-MSCs and preconditioned hUC-MSCs enhanced bacterial clearance. Lung neutrophil influx was decreased with preconditioned hUC-MSCs. [Stem Cells Dev] Abstract

Gene Products Promoting Remyelination Are Up-Regulated in a Cell Therapy Product Manufactured from Banked Human Cord Blood

DUOC-01, a cell product being developed to treat demyelinating conditions, is composed of macrophages that arise from CD14+ monocytes in the mononuclear cell (MNC) population of banked cord blood (CB). The authors demonstrated that expression of multiple gene products that promote remyelination is rapidly up-regulated during manufacturing of DUOC-01 from either MNC or purified CB CD14+ monocytes. [Cytotherapy] Abstract

Taurine Promotes the Cartilaginous Differentiation of Human Umbilical Cord-Derived Mesenchymal Stem Cells In Vitro

Researchers investigated the effect of taurine on the proliferation and chondrogenesis of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) by analyzing cell proliferation, accumulation of glycosaminoglycans and expression of cartilage specific mRNA. The results showed that taurine did not affect the proliferation of hUC-MSCs. [Neurochem Res] Abstract

[snakess]

year end numbers out today and they were great rev up 30%+ earned around .08/sh and an outside source invested $2.5 million or $3.14 per share
Currently $1.77 and also agrees to option to buy another $5 million
International growth off the charts and fourth Q saw many new agreements
Strong Buy with $5.00 target within 1 year. www.hemacare.com

[247MarketAddict]

$HEMA HemaCare Signs Distribution Agreement with Israeli-Based Partner http://www.otcmarkets.net/news-press-releases/hemacare-signs-distribution-agreement-with-israeli-based-partner/

[NoNameStocks]

new blog post on HEMA

I wrote up the highlights from my last post in Aug 2015 through now.

$HEMA is still cheap
http://www.nonamestocks.com/2016/06/hema-is-still-cheap.html

[stocktrademan]

$HEMA recent news/filings

bullish 0.57

$HEMA charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$HEMA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/HEMA/company-info
Ticker: $HEMA

$HEMA extra dd links

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=HEMA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=HEMA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=HEMA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/HEMA/news - http://finance.yahoo.com/q/h?s=HEMA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/HEMA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/HEMA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=HEMA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/HEMA

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/HEMA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/HEMA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/HEMA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=HEMA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=HEMA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/HEMA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=HEMA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=HEMA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=HEMA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=HEMA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=HEMA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/HEMA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=HEMA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/HEMA.HEMA
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=HEMA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/HEMA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/HEMA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/HEMA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/HEMA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/HEMA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=HEMA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=HEMA

[NoNameStocks]

Thanks. Glad you enjoyed my write up. I did read the SA Advisory piece as well. Now let's see some good numbers from HEMA in the spring!

[tsoprano-1]

Dan, I read the No Name report. Very informative. If you are looking for another analysis, check out SA Advisory website. One of last two reports had a nice write up of Hema. I bought some and am considering more. Take care.

T

[NoNameStocks]

I have no association with them

[tsoprano-1]

Dan, you associated with SA Advisory? They just had a write up on Hema. Usually posts under Naga. Hard two believe 2 different people found this little company. Will read your report tomorrow. Thanks for info.

T

[NoNameStocks]

Just realized I did not directly answer your question. They pretty much met my expectations. They have more cash on the bank than I expected. Sales are where they said they'd be at the annual meeting. Margins are about where I thought they'd be. Little more sales and they'll turn a profit

My next expectation is for them to get close to, or achieve, profitability for the 2nd half of 2015. And file a report soon after. I think now that they have restructured and business is doing well they'll start reporting more frequently. I expect them to keep the growth going

My hope is that they turn in a couple years of good numbers then start filing with the SEC again. That'd be great. Not sure they want that but they have a lot of skin in the game so maybe

[NoNameStocks]

Ok I read both documents over and I think they're looking really good. Very close to profitability right now. Maybe they'll turn a profit by the end of this year

Main thing I'm excited about is that they got caught up with filings. Now let's see the 2015 annual results soon after the year ends and keep that ball rolling

Margins are looking good and will hopefully increase as they mature into this new business and as they increase volume.

I wish they disclosed the inside ownership though. I bet they've been buying the past few years since they last disclosed that in a 10k but we don't know.

How funny is the share repurchase program!? $1k spent in 2014...HA!

Dan

[NoNameStocks]

Unfortunately I'm on a business trip so don't have time to check that right now. I did see they released a report which is great news in itself! I'll let you know once I get a chance to read it over

Dan

[Knowledge is King]

Dan, enjoyed your write-up on HEMA. How did today's financial reports square with your expectations? TIA